{"id":455,"date":"2023-01-20T10:39:00","date_gmt":"2023-01-20T18:39:00","guid":{"rendered":"https:\/\/www.adarx.com\/?p=455"},"modified":"2024-12-13T08:33:44","modified_gmt":"2024-12-13T16:33:44","slug":"adarx-pharmaceuticals-announces-dosing-of-first-cohort-in-phase-1-clinical-study-of-adx-324","status":"publish","type":"post","link":"https:\/\/www.adarx.com\/dev\/adarx-pharmaceuticals-announces-dosing-of-first-cohort-in-phase-1-clinical-study-of-adx-324\/","title":{"rendered":"ADARx Pharmaceuticals Announces Dosing of First Cohort in Phase 1 Clinical Study of ADX-324"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">SAN DIEGO\u2013(BUSINESS WIRE)\u2013<a href=\"https:\/\/www.adarx.com\/dev\/\">ADARx Pharmaceuticals, Inc<\/a>., a clinical stage biotechnology company developing RNA-targeting therapeutics, today announced the dosing of the first cohort in a Phase 1 clinical study of ADX-324 for the treatment of hereditary angioedema (HAE). HAE is a rare genetic disease that causes painful, rapid, and potentially life-threatening swelling attacks. \u201cWe are very excited to be advancing our first candidate that utilizes our proprietary PLR\u2122 delivery platform and SPE\u2122 technology into the clinic,\u201d said Zhen Li, President and Chief Executive Officer. \u201cADX-324 represents an innovative and differentiated approach for the treatment of HAE.\u201d \u201cDosing of our first participants in this trial is a major milestone for ADARx; in addition to its potential best-in-class efficacy, our pre-clinical studies in non-human primates have confirmed the likelihood for a bi-annual, and possibly annual, low volume subcutaneous dose regimen for ADX-324,\u201d said Feriandas Greblikas, Vice President of Clinical Development. ADX-324 is a short-interfering RNA (siRNA) designed to reduce the production of PKK, a protein critical to the etiology of HAE. The study is being conducted in Australia as a randomized, placebo-controlled, double-blind, single ascending dose trial in healthy volunteers with an expansion cohort in patients with HAE. The primary objective of the study is to evaluate the safety and tolerability of ADX-324 when administered by subcutaneous injection. More information can be found here: Safety, Tolerability, PK, PD of ADX-324 in Healthy Volunteers and Hereditary Angioedema Patients \u2013 Full Text View \u2013\u00a0<a href=\"http:\/\/clinicaltrials.gov\/\" target=\"_blank\" rel=\"noreferrer noopener\">ClinicalTrials.gov<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>About ADARx<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">ADARx Pharmaceuticals, Inc., located in San Diego, is a clinical stage biotechnology company committed to turning cutting-edge science into life-saving therapeutics. ADARx is developing a proprietary RNA targeting platform, including oligonucleotides for inhibition, degradation, and editing, together with novel oligonucleotide delivery technologies including its PLR\u2122 (\u201cPreeminent Liver RNA\u201d) platform and SPE\u2122 (\u201cSequence Specific Platform Enhancement\u201d) technology. ADARx has a growing pipeline of RNA targeting therapeutics for treating diseases across a range of therapeutic areas including genetic, cardiometabolic, complement-mediated and central nervous system diseases.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Contacts<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">ADARx Contact<br>Roselle Corbaley<br>(877) 232-7974<br><a href=\"mailto:ir@adarx.com\">ir@adarx.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>SAN DIEGO\u2013(BUSINESS WIRE)\u2013ADARx Pharmaceuticals, Inc., a clinical stage biotechnology company developing RNA-targeting therapeutics, today announced the dosing of the first cohort in a Phase 1 clinical study of ADX-324 for the treatment of hereditary angioedema (HAE). HAE is a rare genetic disease that causes painful, rapid, and potentially life-threatening swelling attacks. \u201cWe are very excited [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[4],"tags":[],"class_list":["post-455","post","type-post","status-publish","format-standard","hentry","category-news"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ADARx Pharmaceuticals Announces Dosing of First Cohort in Phase 1 Clinical Study of ADX-324 - ADARx Pharmaceuticals<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ADARx Pharmaceuticals Announces Dosing of First Cohort in Phase 1 Clinical Study of ADX-324 - ADARx Pharmaceuticals\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO\u2013(BUSINESS WIRE)\u2013ADARx Pharmaceuticals, Inc., a clinical stage biotechnology company developing RNA-targeting therapeutics, today announced the dosing of the first cohort in a Phase 1 clinical study of ADX-324 for the treatment of hereditary angioedema (HAE). HAE is a rare genetic disease that causes painful, rapid, and potentially life-threatening swelling attacks. \u201cWe are very excited [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.adarx.com\/dev\/adarx-pharmaceuticals-announces-dosing-of-first-cohort-in-phase-1-clinical-study-of-adx-324\/\" \/>\n<meta property=\"og:site_name\" content=\"ADARx Pharmaceuticals\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-20T18:39:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-13T16:33:44+00:00\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/adarx-pharmaceuticals-announces-dosing-of-first-cohort-in-phase-1-clinical-study-of-adx-324\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/adarx-pharmaceuticals-announces-dosing-of-first-cohort-in-phase-1-clinical-study-of-adx-324\\\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/#\\\/schema\\\/person\\\/31790f93b65593567a6726ca407a0031\"},\"headline\":\"ADARx Pharmaceuticals Announces Dosing of First Cohort in Phase 1 Clinical Study of ADX-324\",\"datePublished\":\"2023-01-20T18:39:00+00:00\",\"dateModified\":\"2024-12-13T16:33:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/adarx-pharmaceuticals-announces-dosing-of-first-cohort-in-phase-1-clinical-study-of-adx-324\\\/\"},\"wordCount\":345,\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/adarx-pharmaceuticals-announces-dosing-of-first-cohort-in-phase-1-clinical-study-of-adx-324\\\/\",\"url\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/adarx-pharmaceuticals-announces-dosing-of-first-cohort-in-phase-1-clinical-study-of-adx-324\\\/\",\"name\":\"ADARx Pharmaceuticals Announces Dosing of First Cohort in Phase 1 Clinical Study of ADX-324 - ADARx Pharmaceuticals\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/#website\"},\"datePublished\":\"2023-01-20T18:39:00+00:00\",\"dateModified\":\"2024-12-13T16:33:44+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/#\\\/schema\\\/person\\\/31790f93b65593567a6726ca407a0031\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/adarx-pharmaceuticals-announces-dosing-of-first-cohort-in-phase-1-clinical-study-of-adx-324\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.adarx.com\\\/dev\\\/adarx-pharmaceuticals-announces-dosing-of-first-cohort-in-phase-1-clinical-study-of-adx-324\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/adarx-pharmaceuticals-announces-dosing-of-first-cohort-in-phase-1-clinical-study-of-adx-324\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ADARx Pharmaceuticals Announces Dosing of First Cohort in Phase 1 Clinical Study of ADX-324\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/#website\",\"url\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/\",\"name\":\"ADARx Pharmaceuticals\",\"description\":\"Providing hope for patients with intractable disease\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/#\\\/schema\\\/person\\\/31790f93b65593567a6726ca407a0031\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/82dca50dfde45fa56a258e833d248704e572b0696fdf3e8ee3811447b2faaf1c?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/82dca50dfde45fa56a258e833d248704e572b0696fdf3e8ee3811447b2faaf1c?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/82dca50dfde45fa56a258e833d248704e572b0696fdf3e8ee3811447b2faaf1c?s=96&d=mm&r=g\",\"caption\":\"admin\"},\"sameAs\":[\"https:\\\/\\\/www.adarx.com\\\/dev\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ADARx Pharmaceuticals Announces Dosing of First Cohort in Phase 1 Clinical Study of ADX-324 - ADARx Pharmaceuticals","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"ADARx Pharmaceuticals Announces Dosing of First Cohort in Phase 1 Clinical Study of ADX-324 - ADARx Pharmaceuticals","og_description":"SAN DIEGO\u2013(BUSINESS WIRE)\u2013ADARx Pharmaceuticals, Inc., a clinical stage biotechnology company developing RNA-targeting therapeutics, today announced the dosing of the first cohort in a Phase 1 clinical study of ADX-324 for the treatment of hereditary angioedema (HAE). HAE is a rare genetic disease that causes painful, rapid, and potentially life-threatening swelling attacks. \u201cWe are very excited [&hellip;]","og_url":"https:\/\/www.adarx.com\/dev\/adarx-pharmaceuticals-announces-dosing-of-first-cohort-in-phase-1-clinical-study-of-adx-324\/","og_site_name":"ADARx Pharmaceuticals","article_published_time":"2023-01-20T18:39:00+00:00","article_modified_time":"2024-12-13T16:33:44+00:00","author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.adarx.com\/dev\/adarx-pharmaceuticals-announces-dosing-of-first-cohort-in-phase-1-clinical-study-of-adx-324\/#article","isPartOf":{"@id":"https:\/\/www.adarx.com\/dev\/adarx-pharmaceuticals-announces-dosing-of-first-cohort-in-phase-1-clinical-study-of-adx-324\/"},"author":{"name":"admin","@id":"https:\/\/www.adarx.com\/dev\/#\/schema\/person\/31790f93b65593567a6726ca407a0031"},"headline":"ADARx Pharmaceuticals Announces Dosing of First Cohort in Phase 1 Clinical Study of ADX-324","datePublished":"2023-01-20T18:39:00+00:00","dateModified":"2024-12-13T16:33:44+00:00","mainEntityOfPage":{"@id":"https:\/\/www.adarx.com\/dev\/adarx-pharmaceuticals-announces-dosing-of-first-cohort-in-phase-1-clinical-study-of-adx-324\/"},"wordCount":345,"articleSection":["News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.adarx.com\/dev\/adarx-pharmaceuticals-announces-dosing-of-first-cohort-in-phase-1-clinical-study-of-adx-324\/","url":"https:\/\/www.adarx.com\/dev\/adarx-pharmaceuticals-announces-dosing-of-first-cohort-in-phase-1-clinical-study-of-adx-324\/","name":"ADARx Pharmaceuticals Announces Dosing of First Cohort in Phase 1 Clinical Study of ADX-324 - ADARx Pharmaceuticals","isPartOf":{"@id":"https:\/\/www.adarx.com\/dev\/#website"},"datePublished":"2023-01-20T18:39:00+00:00","dateModified":"2024-12-13T16:33:44+00:00","author":{"@id":"https:\/\/www.adarx.com\/dev\/#\/schema\/person\/31790f93b65593567a6726ca407a0031"},"breadcrumb":{"@id":"https:\/\/www.adarx.com\/dev\/adarx-pharmaceuticals-announces-dosing-of-first-cohort-in-phase-1-clinical-study-of-adx-324\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.adarx.com\/dev\/adarx-pharmaceuticals-announces-dosing-of-first-cohort-in-phase-1-clinical-study-of-adx-324\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.adarx.com\/dev\/adarx-pharmaceuticals-announces-dosing-of-first-cohort-in-phase-1-clinical-study-of-adx-324\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.adarx.com\/dev\/"},{"@type":"ListItem","position":2,"name":"ADARx Pharmaceuticals Announces Dosing of First Cohort in Phase 1 Clinical Study of ADX-324"}]},{"@type":"WebSite","@id":"https:\/\/www.adarx.com\/dev\/#website","url":"https:\/\/www.adarx.com\/dev\/","name":"ADARx Pharmaceuticals","description":"Providing hope for patients with intractable disease","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.adarx.com\/dev\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.adarx.com\/dev\/#\/schema\/person\/31790f93b65593567a6726ca407a0031","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/82dca50dfde45fa56a258e833d248704e572b0696fdf3e8ee3811447b2faaf1c?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/82dca50dfde45fa56a258e833d248704e572b0696fdf3e8ee3811447b2faaf1c?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/82dca50dfde45fa56a258e833d248704e572b0696fdf3e8ee3811447b2faaf1c?s=96&d=mm&r=g","caption":"admin"},"sameAs":["https:\/\/www.adarx.com\/dev"]}]}},"_links":{"self":[{"href":"https:\/\/www.adarx.com\/dev\/wp-json\/wp\/v2\/posts\/455","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.adarx.com\/dev\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.adarx.com\/dev\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.adarx.com\/dev\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.adarx.com\/dev\/wp-json\/wp\/v2\/comments?post=455"}],"version-history":[{"count":2,"href":"https:\/\/www.adarx.com\/dev\/wp-json\/wp\/v2\/posts\/455\/revisions"}],"predecessor-version":[{"id":506,"href":"https:\/\/www.adarx.com\/dev\/wp-json\/wp\/v2\/posts\/455\/revisions\/506"}],"wp:attachment":[{"href":"https:\/\/www.adarx.com\/dev\/wp-json\/wp\/v2\/media?parent=455"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.adarx.com\/dev\/wp-json\/wp\/v2\/categories?post=455"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.adarx.com\/dev\/wp-json\/wp\/v2\/tags?post=455"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}